Genitourinary Cancer

SAMETA (D5086C00001)

A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma)

Trial overview


Genitourinary Cancer


A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC) (SAMETA)

Eligibility criteria

  • Histologically confirmed unresectable and locally advanced or metastatic PRCC
  • PRCC must be centrally confirmed as MET-driven using a sponsor-designated central
    laboratory validated NGS assay
  • No prior systemic anti-cancer treatment in the metastatic setting; no prior exposure
    to MET inhibitors, Durvalumab or Sunitinib in any setting
    Karnofsky Score >70
  • At least one lesion, not previously irradiated, that can be accurately measured at
  • Adequate organ and bone marrow function
  • Life expectancy =12weeks at Day 1

Further information

Please click here for more information.


Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.